Metraipolis › archive › dc_97e918b73bc2
Efficacy and safety of zuberitamab in the treatment of primary membranous nephropathy: an observational study — Europe PMC PMID:41601658
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41601658
- DOI
- 10.3389/fimmu.2025.1741564
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T21:21:30.209Z
- SHA-256 of the archived text
a2e4b180e5d0ca6b41eb109e0f4ce35558fc34779a87691a64c65a5b06162bd0- Stable URL of this page
https://metraipolis.com/documento/dc_97e918b73bc2
How to cite
Efficacy and safety of zuberitamab in the treatment of primary membranous nephropathy: an observational study — Europe PMC PMID:41601658 — Europe PMC (en), https://europepmc.org/article/MED/41601658 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_97e918b73bc2 (Metraipolis archive dc_97e918b73bc2, sha256 a2e4b180e5d0ca6b41eb109e0f4ce35558fc34779a87691a64c65a5b06162bd0)
BibTeX
@misc{dc97e918b73bc2,
title = {Efficacy and safety of zuberitamab in the treatment of primary membranous nephropathy: an observational study — Europe PMC PMID:41601658},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41601658},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_97e918b73bc2; sha256 a2e4b180e5d0ca6b41eb109e0f4ce35558fc34779a87691a64c65a5b06162bd0},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41601658. Agents can read the archived copy with the MCP tool read_document.